Martina Doubkova1, Eva Kriegova2, Simona Littnerova3, Petra Schneiderova2, Martina Sterclova4, Vladimir Bartos5, Martina Plackova6, Monika Zurkova7, Radka Bittenglova8, Vladimira Lostaková7, Lenka Siskova9, Pavlina Lisa10, Hana Suldova11, Michael Doubek12, Jana Psikalova13, Tomas Snizek14, Pavlina Musilova14, Martina Vasakova4. 1. Department of Pulmonology and Physiology, Faculty of Medicine, Masaryk University and University Hospital Brno, Jihlavská 20, 625 00 Brno, Czech Republic. 2. Department of Immunology, Faculty of Medicine and Dentistry, Palacky University in Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. 3. Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. 4. Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. 5. Department of Pneumology, Faculty of Medicine in Hradec Králové, Charles University, Prague, Czech Republic. 6. Department of Pneumology, Faculty of Medicine, University Hospital in Ostrava, Ostrava, Czech Republic. 7. Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. 8. Department of Respiratory Diseases, Faculty of Medicine in Pilsen, Charles University and University Hospital Pilsen, Pilsen, Czech Republic. 9. Department of Respiratory Diseases, Tomáš Baťa Regional Hospital, Zlín, Czech Republic. 10. Department of Pneumology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. 11. Pulmonary Department, České Budějovice Hospital, Ceske Budejovice, Czech Republic. 12. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. 13. PneumoAllergology Department, Kroměříž Hospital, Kromeriz, Czech Republic. 14. Department of Respiratory Diseases, Jihlava Hospital, Jihlava, Czech Republic.
Abstract
BACKGROUND: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of common profibrotic polymorphisms in MUC5B (mucin 5B, rs35705950) and DSP (desmoplakin, rs2076295) on antifibrotic treatment outcomes in IPF. METHODS: MUC5B rs35705950 and DSP rs2076295 were assessed in IPF patients (n = 210, 139 men/71 women) from the Czech EMPIRE registry and age- or sex-matched healthy individuals (n = 205, 125 men/80 women). Genetic data were collated with overall survival (OS), acute exacerbation episodes, worsening lung function and antifibrotic treatment. RESULTS: We confirmed overexpression of the MUC5B rs35705950*T allele (55.2% versus 20.9%, p < 0.001) and the DSP rs2076295*G allele (80.4% versus 68.3%, p < 0.001) in IPF compared with controls. On antifibrotic drugs, lower mortability was observed in IPF patients with DSP G* allele (p = 0.016) and MUC5B T* allele (p = 0.079). Carriers of the DSP rs2076295*G allele benefitted from nintedanib treatment compared with TT genotype by a longer OS [hazard ratio (HR) = 7.99; 95% confidence interval (CI) = 1.56-40.90; p = 0.013] and a slower decline in lung function (HR = 8.51; 95% CI = 1.68-43.14; p = 0.010). Patients with a TT genotype (rs2076295) benefitted from treatment with pirfenidone by prolonged OS (p = 0.040; HR = 0.35; 95% CI = 0.13-0.95) compared with nintedanib treatment. Both associations were confirmed by cross-validation analysis. After stratifying by MUC5B rs35705950*T allele carriage, no difference in treatment outcome was observed for nintedanib or pirfenidone (p = 0.784). In the multivariate model, smoking, age, forced vital capacity (FVC) and DLCO (diffuse lung capacity) at the IPF diagnosis were associated with survival. CONCLUSION: Our real-world study showed that IPF patients with MUC5B T* allele or DSP G* allele profit from antifibrotic treatment by lower mortability. Moreover, carriers of the DSP rs2076295*G allele benefit from treatment with nintedanib, and TT genotype from treatment with pirfenidone. MUC5B rs35705950 did not impact the outcome of treatment with either nintedanib or pirfenidone. Our single-registry pilot study should be confirmed with an independent patient cohort.
BACKGROUND: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of common profibrotic polymorphisms in MUC5B (mucin 5B, rs35705950) and DSP (desmoplakin, rs2076295) on antifibrotic treatment outcomes in IPF. METHODS: MUC5B rs35705950 and DSP rs2076295 were assessed in IPF patients (n = 210, 139 men/71 women) from the Czech EMPIRE registry and age- or sex-matched healthy individuals (n = 205, 125 men/80 women). Genetic data were collated with overall survival (OS), acute exacerbation episodes, worsening lung function and antifibrotic treatment. RESULTS: We confirmed overexpression of the MUC5B rs35705950*T allele (55.2% versus 20.9%, p < 0.001) and the DSP rs2076295*G allele (80.4% versus 68.3%, p < 0.001) in IPF compared with controls. On antifibrotic drugs, lower mortability was observed in IPF patients with DSP G* allele (p = 0.016) and MUC5B T* allele (p = 0.079). Carriers of the DSP rs2076295*G allele benefitted from nintedanib treatment compared with TT genotype by a longer OS [hazard ratio (HR) = 7.99; 95% confidence interval (CI) = 1.56-40.90; p = 0.013] and a slower decline in lung function (HR = 8.51; 95% CI = 1.68-43.14; p = 0.010). Patients with a TT genotype (rs2076295) benefitted from treatment with pirfenidone by prolonged OS (p = 0.040; HR = 0.35; 95% CI = 0.13-0.95) compared with nintedanib treatment. Both associations were confirmed by cross-validation analysis. After stratifying by MUC5B rs35705950*T allele carriage, no difference in treatment outcome was observed for nintedanib or pirfenidone (p = 0.784). In the multivariate model, smoking, age, forced vital capacity (FVC) and DLCO (diffuse lung capacity) at the IPF diagnosis were associated with survival. CONCLUSION: Our real-world study showed that IPF patients with MUC5B T* allele or DSP G* allele profit from antifibrotic treatment by lower mortability. Moreover, carriers of the DSP rs2076295*G allele benefit from treatment with nintedanib, and TT genotype from treatment with pirfenidone. MUC5B rs35705950 did not impact the outcome of treatment with either nintedanib or pirfenidone. Our single-registry pilot study should be confirmed with an independent patient cohort.
Entities:
Keywords:
IPF; antifibrotic treatment; desmoplakin; mucin 5; single nucleotide polymorphisms
Authors: Jonathan A Kropski; Lisa R Young; Joy D Cogan; Daphne B Mitchell; Lisa H Lancaster; John A Worrell; Cheryl Markin; Na Liu; Wendi R Mason; Tasha E Fingerlin; David A Schwartz; William E Lawson; Timothy S Blackwell; John A Phillips; James E Loyd Journal: Am J Respir Crit Care Med Date: 2017-06-01 Impact factor: 21.405
Authors: Patrick D Mitchell; Jeeban P Das; David J Murphy; Michael P Keane; Seamas C Donnelly; Jonathan D Dodd; Marcus W Butler Journal: Respir Care Date: 2014-11-11 Impact factor: 2.258
Authors: Frank Hilberg; Gerald J Roth; Martin Krssak; Susanna Kautschitsch; Wolfgang Sommergruber; Ulrike Tontsch-Grunt; Pilar Garin-Chesa; Gerd Bader; Andreas Zoephel; Jens Quant; Armin Heckel; Wolfgang J Rettig Journal: Cancer Res Date: 2008-06-15 Impact factor: 12.701
Authors: Mareike Lehmann; Lara Buhl; Hani N Alsafadi; Stephan Klee; Sarah Hermann; Kathrin Mutze; Chiharu Ota; Michael Lindner; Jürgen Behr; Anne Hilgendorff; Darcy E Wagner; Melanie Königshoff Journal: Respir Res Date: 2018-09-15
Authors: Tasha E Fingerlin; Elissa Murphy; Weiming Zhang; Anna L Peljto; Kevin K Brown; Mark P Steele; James E Loyd; Gregory P Cosgrove; David Lynch; Steve Groshong; Harold R Collard; Paul J Wolters; Williamson Z Bradford; Karl Kossen; Scott D Seiwert; Roland M du Bois; Christine Kim Garcia; Megan S Devine; Gunnar Gudmundsson; Helgi J Isaksson; Naftali Kaminski; Yingze Zhang; Kevin F Gibson; Lisa H Lancaster; Joy D Cogan; Wendi R Mason; Toby M Maher; Philip L Molyneaux; Athol U Wells; Miriam F Moffatt; Moises Selman; Annie Pardo; Dong Soon Kim; James D Crapo; Barry J Make; Elizabeth A Regan; Dinesha S Walek; Jerry J Daniel; Yoichiro Kamatani; Diana Zelenika; Keith Smith; David McKean; Brent S Pedersen; Janet Talbert; Raven N Kidd; Cheryl R Markin; Kenneth B Beckman; Mark Lathrop; Marvin I Schwarz; David A Schwartz Journal: Nat Genet Date: 2013-04-14 Impact factor: 38.330
Authors: Monika Zurkova; Eva Kriegova; Vitezslav Kolek; Vladimira Lostakova; Martina Sterclova; Vladimir Bartos; Martina Doubkova; Ilona Binkova; Michal Svoboda; Jana Strenkova; Marketa Janotova; Martina Plackova; Ladislav Lacina; Vladimir Rihak; Frantisek Petrik; Pavlina Lisa; Radka Bittenglova; Richard Tyl; Gustav Ondrejka; Hana Suldova; Jaroslav Lnenicka; Jana Psikalova; Tomas Snizek; Jiri Homolka; Renata Kralova; Jan Kervitzer; Martina Vasakova Journal: Respir Res Date: 2019-01-21